An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) - CAMBRIA-2

Study identifier:D8535C00001

ClinicalTrials.gov identifier:NCT05952557

EudraCT identifier:N/A

CTIS identifier:2023-504031-41

Recruiting

Official Title

CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease

Medical condition

Breast cancer, early breast cancer

Phase

Phase 3

Healthy volunteers

Study drug

Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane, Abemaciclib

Sex

All

Estimated Enrollment

5500

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 05 Oct 2023

Estimated Primary Completion Date: 04 Mar 2030

Estimated Study Completion Date: 06 May 2037

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2024 by AstraZeneca

Collaborators

Austrian Breast and Colorectal Cancer Study Group (ABCSG)

Inclusion and exclusion criteria

Inclusion Criteria

- Women and Men; ≥18 years at the time of screening (or per national guidelines)
- Histologically confirmed ER+/HER2- early-stage resected invasive breast cancer with absence of any evidence of metastatic disease as defined in the protocol.
- Completed adequate (definitive) locoregional therapy (surgery with or without radiotherapy) for the primary breast tumour(s), with or without (neo)adjuvant chemotherapy.
- Patients must be randomised within 12 months of definitive breast surgery.
- Patients may have received up to 12 weeks of endocrine therapy prior to randomisation.
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
- Adequate organ and bone marrow function

Exclusion Criteria

- Inoperable locally advanced or metastatic breast cancer
- Pathological complete response following treatment with neoadjuvant therapy
- History of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix or considered a very low risk of recurrence per investigator judgement) unless in complete remission with no therapy for a minimum of 5 years from the date of randomisation
- Any evidence of severe or uncontrolled systemic diseases which, in the investigator’s opinion precludes participation in the study or compliance "
- Known LVEF <50% with heart failure NYHA Grade ≥2.
- Mean resting QTcF interval > 480 ms at screening
- Concurrent exogenous reproductive hormone therapy or non topical hormonal therapy for non-cancer-related conditions
- Any concurrent anti-cancer treatment not specified in the protocol with the exception of bisphosphonates (e.g. zoledronic acid) or RANKL inhibitors ( eg, denosumab)
- Previous treatment with camizestrant, investigational SERDs/investigational ER targeting agents, or fulvestrant
- Currently pregnant (confirmed with positive serum pregnancy test) or breastfeeding.
- Patients with known hypersensitivity to active or inactive excipients of camizestrant or drugs with a similar chemical structure or class to camizestrant. In pre-/peri-menopausal female and male patients, known hypersensitivity or intolerance to LHRH agonists that would preclude the patient from receiving any LHRH agonist.

Sort by status

No locations available

Arms	Assigned Interventions
Active Comparator: Arm A: standard endocrine therapy of investigator´s choice ± abemaciclib standard endocrine therapy of investigator’s choice (aromatase inhibitors [AI; exemestane, letrozole, anastrozole] or tamoxifen) ± abemaciclib	Drug: Tamoxifen Tamoxifen. Comparator. Administered orally Drug: Anastrozole Anastrozole. Comparator. Administered orally Drug: Letrozole Letrozole. Comparator. Administered orally Drug: Exemestane Exemestane. Comparator. Administered orally Drug: Abemaciclib Abemaciclib adjuvant treatment Administered orally
Experimental: Arm B: camizestrant ± abemaciclib camizestrant ± abemaciclib	Drug: Camizestrant Camizestrant. Experimental. Administered orally Other Name: AZD9833 Drug: Abemaciclib Abemaciclib adjuvant treatment Administered orally

Documents available

Breast Cancer Study Locator details (for US)
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]

Contact Backup

AstraZeneca Breast Cancer Study Locator Service

1-877-400-4656